YAP1 and liver disorder: However, YAP as a therapeutic target in liver disease is discussed controversially due to the fact that clinically tolerable pharmacological inhibitors are lacking, and harmful effects were reported for the BDL model of acute and complete obstructive cholestasis [11, 15].